Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has provided a shareholder update from CEO Amir Reichman detailing significant growth in its contract development and manufacturing organization (CDMO) business, strengthened liquidity, and an extended operating runway. The announcement, issued via Scinai Immunotherapeutics (NASDAQ: SCNI), underscores the company's progress in expanding its service offerings and securing its financial position.
As of October 20, 2026, Scinai reported approximately $8.1 million in committed customer orders, a more than 300% increase from $1.9 million at year-end 2025. This growth was driven by a new agreement with a U.S.-based biopharmaceutical company that includes approximately $5.1 million in committed base service fees. The agreement also contemplates approximately $5.85 million in additional, uncommitted services, bringing the combined potential opportunity to more than $10 million, subject to further agreements and project milestones. This substantial backlog provides revenue visibility and signals growing customer confidence in Scinai's manufacturing capabilities.
In addition to the operational progress, Scinai reported approximately $5.3 million in combined net proceeds from recent equity financings, which included a standby equity purchase agreement drawdown and a private placement with warrant exercises. Management estimates that current cash resources and expected customer payments will support operations through late 2027, potentially extending into the third quarter of 2028 if additional project phases are activated and delivered. This extended runway reduces near-term financing risk and allows the company to focus on executing its growth strategy.
The company remains focused on expanding its CDMO customer base, improving facility utilization, and pursuing capital-efficient development of its NanoAb immunotherapy platform through grants and partnerships. Scinai operates through Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies from facilities in Jerusalem and Yavne, Israel. The company is also advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.
For investors, the update highlights Scinai's ability to convert its CDMO capabilities into committed revenue while maintaining a lean capital structure. The significant increase in orders and the extended cash runway may bolster confidence in the company's near-term stability and growth prospects. The full press release can be accessed at https://ibn.fm/3C1F4, and ongoing news and updates are available in the company's newsroom at https://ibn.fm/SCNI.
The announcement was distributed by InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers services including editorial syndication to 5,000+ outlets and social media distribution to millions of followers. These services help companies like Scinai reach a broad audience of investors and industry stakeholders. For full terms and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
